Emergent BioSolutions Inc. (EBS)

New York Stock Exchange:
EBS
| Latest update: Mar 9, 2026, 7:10 PM

Price Chart

$8.15

1.52%
(1 month)

Top Shareholders

BlackRock, Inc.
8.10%
T. Rowe Price Group, Inc.
6.95%
The Vanguard Group, Inc.
6.80%
State Street Corp.
5.13%
American Century Cos., Inc.
4.64%
Nomura Holdings, Inc.
4.40%
Dimensional Holdings, Inc.
4.29%
The Charles Schwab Corp.
3.08%

Sentiment for EBS

News
Social

Buzz Talk for EBS

Today

Social Media

General

Stock events for Emergent BioSolutions, Inc. (EBS)

Emergent BioSolutions' stock price has been volatile over the past six months. Key events include the release of Q4 and full year 2025 financial results which missed estimates and the announcement of a stock repurchase program and contract awards with the Government of Canada. The company received FDA approval for NARCAN Nasal Spray multipacks and a new carrying case. Emergent BioSolutions announced a paydown of its term loan principal and received a delivery order to supply BioThrax to the U.S. Department of War. HC Wainwright reaffirmed a buy rating, while Weiss Ratings lowered the rating to sell and Wall Street Zen downgraded the stock to hold. John D. Fowler, Jr. was appointed as a Board Director.

Demand Seasonality affecting Emergent BioSolutions, Inc.’s stock price

Specific details regarding demand seasonality are not explicitly provided. However, the company's business model suggests that demand may be influenced by government procurement cycles, national preparedness initiatives, and the emergence of health crises. The company has secured numerous modifications to MCM contracts, indicating sustained demand in the global biodefense market. NARCAN's performance has been temporarily impacted by softer demand amid government shutdown-related uncertainties, and the company faces risks from increased generic competition for NARCAN.

Overview of Emergent BioSolutions, Inc.’s business

Emergent BioSolutions, Inc. is a global life sciences company focused on preparedness and response solutions for public health threats, operating in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. The company's business is segmented into Commercial Products, Medical Countermeasure (MCM) Products, and Services (Bioservices). Key products include NARCAN Nasal Spray, BioThrax, ACAM2000, Vaxchora, Anthrasil, KLOXXADO nasal spray and Anthim. The company also provides contract development and manufacturing organization (CDMO) services.

EBS’s Geographic footprint

Emergent BioSolutions has a global presence with solutions in the United States, Canada, and internationally. Its headquarters are in Gaithersburg, Maryland, and it has facilities in various locations worldwide, including Canada, Portugal, and Singapore.

EBS Corporate Image Assessment

Specific information detailing Emergent BioSolutions' brand reputation is not explicitly available. However, the company's focus on public health threats, partnerships with government agencies, and role in national preparedness programs suggest a reputation tied to critical public health and biodefense initiatives. The company's efforts in its multiyear transformation plan indicate ongoing efforts to improve its standing.

Ownership

Emergent BioSolutions is a publicly traded company with a diverse shareholder base, including institutional, retail, and individual investors. Major institutional owners include BlackRock, Inc., The Vanguard Group Inc., and State Street Corp. The largest individual shareholder is Fuad El-Hibri, who owns 49.71% of the company.

FAQ

What is the current stock price of Emergent BioSolutions, Inc.?

As of the latest update, Emergent BioSolutions, Inc.'s stock is trading at $8.15 per share.

What’s happening with Emergent BioSolutions, Inc. stock today?

Today, Emergent BioSolutions, Inc. stock is down by -1.52%, possibly due to news.

What is the market sentiment around Emergent BioSolutions, Inc. stock?

Current sentiment around Emergent BioSolutions, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Emergent BioSolutions, Inc.'s stock price growing?

Over the past month, Emergent BioSolutions, Inc.'s stock price has decreased by -1.52%.

How can I buy Emergent BioSolutions, Inc. stock?

You can buy Emergent BioSolutions, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol EBS

Who are the major shareholders of Emergent BioSolutions, Inc. stock?

Major shareholders of Emergent BioSolutions, Inc. include institutions such as BlackRock, Inc. (8.10%), T. Rowe Price Group, Inc. (6.95%), The Vanguard Group, Inc. (6.80%) ... , according to the latest filings.